α5β1 x ANGPTL3

This is a Phase IIa proof-of-concept study with 4 treatment arms (TA1-4) designed to determine the efficacy of LNA043 in patients with symptomatic knee OA with inflammation as determined by MRI. The objectives of the study include: Evaluate whether the efficacy of i.a. LNA043 can be determined in patients with inflammatory knee OA Evaluate whether the potential adverse effects of inflammation can be overcome by co-administering an anti-inflammatory drug (i.a. canakinumab) Evaluate the efficacy of i.a. canakinumab in relieving pain and other clinical symptoms and improving function